Design, Synthesis, and Bioactivity Evaluation of a Palmitoyltransferase Inhibitor Based on the PAP Structure
Chemistry & Biodiversity · 2026-02 · 23 (2)
DOI: 10.1002/cbdv.202501311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 24.02.2026. Verfasst von Yibo Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Baoding, China. Hauptthemen laut MEDLINE: Enzyme Inhibitors, Drug Design, Antineoplastic Agents, Acyltransferases. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hebei Province, Natural Science Interdisciplinary Research Program of Hebei University.
Abstract (Originalsprache)
Protein palmitoylation is a crucial posttranslational lipid modification and exerts an influence on various cancer‐related factors and is directly implicated in the pathogenesis of malignant tumors. The study used the original ligand phosphate‐adenosine‐5′‐diphosphateas (PAP) of palmitoyltransferase (DHHC) as the lead compound, designed and synthesized two series of pyrazolo[3,4‐ d ]pyrimidine derivatives as DHHC inhibitors. Among them, compound C9 displayed superior DHHC inhibitory activity compared with PAP, and the best antiproliferative activity against MC38 cells with low toxicity. In vitro, it manifested excellent abilities in inhibiting cancer cell migration and invasion, promoting cancer cell apoptosis, and arresting the cells in the G 0 /G 1 phase. Molecular docking studies showed that C9 could occupy the PAP binding site and enhance interactions with surrounding amino acid residues. Molecular dynamics simulations showed that C9 could stably bind to DHHC. These findings highlight the potential of C9 as a novel and potent palmitoyltransferase inhibitor that deserves further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Baoding, China.
- State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis, Ministry of Education, Hebei University, Baoding, China.
- State Key Laboratory of New Pharmaceutical Preparations and Excipients, Hebei University, Baoding, China.
ORCID-Profile: Yali Song
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hebei Province
- Natural Science Interdisciplinary Research Program of Hebei University
- Innovation Team Project of Hebei University
- Undergraduate Innovation and Entrepreneurship Training Program of Hebei Province
- State Key Laboratory of Natural and Biomimetic Drugs
Zitieren
APA
Zhang, Y., Liu, H., Li, J., Han, X., Ran, Z., Zhang, L., Liu, Z., Yang, K., Song, X., & Song, Y. (2026). Design, Synthesis, and Bioactivity Evaluation of a Palmitoyltransferase Inhibitor Based on the PAP Structure. Chemistry & Biodiversity, 23(2). https://doi.org/10.1002/cbdv.202501311
Vancouver
Zhang Y, Liu H, Li J, Han X, Ran Z, Zhang L, et al. Design, Synthesis, and Bioactivity Evaluation of a Palmitoyltransferase Inhibitor Based on the PAP Structure. Chemistry & Biodiversity. 2026;23(2). doi:10.1002/cbdv.202501311
BibTeX
@article{Zhang2026,
author = {Zhang, Yibo and Liu, Han and Li, Jinze and Han, Xinyue and Ran, Zilu and Zhang, Liangren and Liu, Zhenming and Yang, Kan and Song, Xueqing and Song, Yali},
title = {Design, Synthesis, and Bioactivity Evaluation of a Palmitoyltransferase Inhibitor Based on the PAP Structure},
journal = {Chemistry & Biodiversity},
year = {2026},
volume = {23},
number = {2},
doi = {10.1002/cbdv.202501311}
}
EUVIMED